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Purpose: Docetaxel, a chemotherapeutic agent, induces high rates of transient chemotherapy-induced amenorrhea
(CIA) when used as adjuvant chemotherapy for premenopausal women with breast cancer. Clinical laboratory data
to assess the hormonal environment implicated in inducing transient CIA was assessed.
Methods: An observational study was conducted in 35 premenopausal women with hormone-responsive breast
cancer who were receiving adjuvant docetaxel/cyclophosphamide (TC) chemotherapy. Serum estradiol and follicular
stimulating hormone (FSH) levels were measured at one (n = 6) or two (n = 29) time point(s) around the completion
of chemotherapy.
Results: As early as week 6 after the start of chemotherapy, just before the third TC cycle, serum estradiol levels
were invariably suppressed (median of 5.5 pg/ml, n = 15, range <5–18.7 pg/ml) and FSH levels increased (median
of 63.9 mIU/ml, range 24.5–127.4 mIU/ml), indicative of ovarian suppression to the menopausal levels.
Subsequently, at 9 and 12 weeks, serum estradiol levels were suppressed to a median of 6.6 pg/ml (n = 49,
range <5–17.3 pg/ml), while FSH levels were high (median of 66.8 mIU/ml, range 29.2–134.5 mIU/ml). There was a
significant Spearman’s correlation (ρ = 0.95, n = 29, p < 0.01) of high serum FSH levels (24.5–134.5 mIU/ml) between
two time points of repeated measurements in 29 patients. TC chemotherapy induced rapid ovarian suppression
with the formation of a high and stable plateau in serum FSH levels from week 6 to week 12.
Conclusions: Recovery from transient CIA post-therapy may be partially attributed to high, stable FSH levels that
occurred as early as after completion of the second TC chemotherapy cycle.
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Breast cancer is a heterogeneous disease for which
optimal treatment must be tailored to a specific breast
cancer type (Goldhirsch et al. 2007; Nguyen et al. 2008).
Age and menstrual status are taken into consideration
when treatment is being planned for patients with early
breast cancer. Docetaxel-containing chemotherapy, TC
(docetaxel/cyclophosphamide), has been reported to be* Correspondence: 2056@nakatsu.saiseikai.or.jp
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reproduction in any medium, provided the origassociated with a better overall survival benefit com-
pared with second generation chemotherapy, AC (doxo-
rubicin/cyclophosphamide), and has become one of the
standard adjuvant chemotherapy regimens for the treat-
ment of early breast cancer (Jones et al. 2006; Jones
et al. 2009).
Chemotherapy-induced amenorrhea (CIA) varies in
type and onset. Amenorrhea was shown to be transient,
lasting for 3 (Parulekar et al. 2005; Yoo et al. 2013) or 6
months (Swain & Land 2009; Park et al. 2012; Swain
et al. 2010a; Swain et al. 2010b), or persistent. Onset ofer. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
inal work is properly credited.
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therapy completion to up to 24 months of follow-up. At
the 12-month assessment, after either first or second-
generation chemotherapy, 41% of patients who were
not amenorrheic at the 6-month assessment had CIA
(Parulekar et al. 2005). Docetaxel-containing chemother-
apy caused amenorrhea at a relatively high rate soon after
chemotherapy completion, but at the later periods, 12 and
36 months, the rate of CIA was relatively lower (Berliere
et al. 2008; Han et al. 2009). Most (92%) premenopausal
women treated with AC followed by docetaxel in the
NSABP B-30 clinical trial were reported to become amen-
orrheic for a short period (<3 months), while 45.3% of
women <40 years of age resumed menses at the 2 year
assessment (Swain & Land 2009). Anderson et al. demon-
strated that serum estradiol concentrations decreased at
six months only in women who had completed a six-month
course of a docetaxel-containing regimen (anthracycline-
based chemotherapy followed by docetaxel) (Anderson
et al. 2006). It may be possible to determine if there was a
brief period of amenorrhea, which the patient might not
have recorded even if there was no vaginal bleeding at the
time of TC chemotherapy completion, by monitoring
ovarian function.
CIA has been associated with clinically important effects
on symptoms and quality of life (Knobf 2006). We sought
to describe our own experience in this observational
study by monitoring serum estradiol and follicle-stimulating
hormone (FSH) levels to provide information on changes
in serum estradiol levels to deal with the predictable
symptoms caused by such hormonal changes, and to gain
insight into the underlying hormonal changes due to
current CIA.
This study was limited by the small number of pa-
tients; however, to the best of our knowledge, this is the
first report to show that TC chemotherapy in premeno-
pausal women with hormone-responsive breast cancer
induced ovarian suppression at the time of chemother-
apy completion, as assessed using clinical laboratory
measurements of serum estradiol and FSH.
Patients and methods
Between May 2009 and March 2014, 35 consecutive pre-
menopausal patients with ER-positive early breast cancer
at medium risk who had completed adjuvant TC chemo-
therapy treatment after surgery were analyzed. Premeno-
pausal status of these patients was defined in this cohort
as having regular menses before surgery.
TC chemotherapy consisted of intravenous injections of
docetaxel (75 mg/m2) and cyclophosphamide (600 mg/
m2) every three weeks for four cycles (Jones et al. 2006).
All 35 patients received complete treatment as defined per
protocol. ER and PR status was determined using immu-
nohistochemistry and HER2/neu status was determinedusing fluorescence in situ hybridization (FISH). Tumors
were classified as ER-negative when immunohistochemical
quantitation showed <1% ER-stained cells. The median
age at surgery was 43 years-old and all patients had regu-
lar menses before surgery. Their serum estradiol and FSH
levels were measured at 6, 9 and 12 weeks after the start
of chemotherapy. Patient baseline characteristics are
shown in Table 1.
Our original study aim was to monitor changes in serum
FSH and estradiol levels three weeks after completion of
TC chemotherapy to gather information on baseline levels
of the ovarian function, to be compared with levels at the
resumption of menses, and all patients gave their consent
on this basis. We expanded our study plan to include two
time points from earlier cycles of chemotherapy to help
pinpoint when estradiol suppression had occurred, be-
cause an unexpected stable decline of serum estradiol
levels was observed in all patients. Consent to take these
additional serum samples was obtained from 29 patients.
Fasting morning samples were collected at weeks 6 and 9,
just before the start of the third and fourth cycles of
chemotherapy, concomitant with regular white blood cell
count checks before chemotherapy. Blood samples were
also collected from patients not fasting at week 12, three
weeks after the forth cycle of TC chemotherapy had been
administered.
Estradiol determination
Serum estradiol levels were determined at BML Inc.
(Tokyo, Japan) using a direct immunoassay performed
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Chicago, IL), which has an analytic sensitivity of 10 pg/ml,
according to the manufacturer’s protocol, with an ex-
tended standard curve to allow for a lower limit of
detection of 5 pg/ml.Statistical methods
The sample size was too small to use an unpaired statis-
tical test; therefore, Spearman’s rank correlation coefficient
(ρ) was calculated using repeated measurements of serum
FSH levels in 29 women. From the ρ value, t was obtained.Results
Serum FSH levels above 40 mIU/ml and serum estradiol
levels below 39 pg/ml were commonly accepted as base-
line values indicating menopausal status. Figure 1 shows
serum estradiol and FSH levels from 35 patients at 6, 9
and 12 weeks after the first cycle that TC chemotherapy
was administered. The final 15 patients (ages 32–50, me-
dian 44 years old) were monitored at two time points,
weeks 6 and 9 after the first cycle of chemotherapy.
Serum estradiol levels decreased to below 18.7 pg/ml
(median 5.5 pg/ml, range <5–18.7 pg/ml, n = 15) and
FSH levels increased to a median of 63.9 mIU/ml (24.5–
127.4 mIU/ml) as early as week 6, after two cycles of
chemotherapy. At week 9, serum estradiol levels de-
creased to a median of 6.6 pg/ml (range <5–16.9 pg/ml,
n = 29) and serum FSH levels increased to a median of
66.8 mIU/ml (range 33.9–134.5 mIU/ml). Furthermore,
at week 12, 3 weeks after administration of the forth
cycle of TC chemotherapy, estradiol levels remained de-
creased with a median value of 6.6 pg/ml (range <5–17.3
pg/ml, n = 20) and FSH levels were still increased with a
median value of 66.1 mIU/ml (range 29.2–101 mIU/ml).Figure 1 Serum FSH and estradiol levels following the second, third orWhile Figure 1 indicated that TC chemotherapy
resulted in rapid ovarian suppression, the major obstacle
to find a statistically significant difference was the small
number of patients in the study. In addition, the method
used to measure serum estradiol levels had limited sensi-
tivity with a lower limit of detection of 5 pg/ml. Figure 2
shows inter-individual changes in serum estradiol and
FSH levels at weeks 6, 9 and 12 in 29 patients with two
time point assessments. There was a significant Spearman’s
rank correlation coefficient (ρ = 0.95, t = 15.3, n = 29,
p < 0.01) between 6 and 9 weeks and/or between 9 and 12
weeks of high serum FSH levels (43.5–102.9 mIU/ml).
FSH and estradiol levels fluctuated depending on the
phase of the menstrual cycle; therefore, a significant cor-
relation in high serum FSH levels between each of the two
time points indicated that these FSH levels may be the
maximum that can occur in response to rapid estradiol
suppression during the early period of TC chemotherapy.
Menstruation
At the 2-year assessment, five women (ages 32–48, me-
dian 39) resumed menses, confirmed by laboratory mea-
surements, among 20 patients who received tamoxifen
only without LHRH analog treatment (ages 32–52, me-
dian 45) after chemotherapy completion, with the fastest
occurring at week 21. Discordance between laboratory
data and patient-recorded vaginal bleeding was observed
in two patients who had menstrual bleeding at week 7
among 15 patients whose laboratory data showed severe
ovarian dysfunction at week 6.
Discussion
This study included a small cohort of 35 patients; however,
our findings that ovarian suppression at the time of
chemotherapy completion was induced in patients treatedfourth cycles of TC chemotherapy in 35 premenopausal women.
Figure 2 Bars show inter-individual changes in serum estradiol and FSH levels in later 29 patients who were monitored 2 time-points.
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by previous observations in which docetaxel resulted in
higher rates of transient CIA when used as adjuvant
chemotherapy for premenopausal women with breast
cancer (Berliere et al. 2008; Han et al. 2009).
It has been reported that cytotoxic agents, especially
anthracyclines and alkylating agents such as cyclophos-
phamide, induce amenorrhea, potentially by activating
apoptotic oocyte death in primordial follicles, which
damages the ovarian reserve (Oktem & Oktay 2007).
However, younger patients were found to be resistant to
CIA because they have a larger primordial follicle pool
(Oktem & Oktay 2007). In studies of ovarian function
after chemotherapy without docetaxel, the decrease in
serum estradiol concentrations and increase in FSH
levels showed greater variations than our observations
(Yoo et al. 2013; Yu et al. 2010).
Mechanisms of gonadal toxicity caused by chemother-
apeutic agents are complex. Colleoni et al. reported that
three cycles of dose-intensive epirubicin and cyclophos-
phamide with filgrastim and progenitor cell support
significantly improved DFS only in patients with ER-
positive disease, and resulted in higher rates of CIA
even in patients <40 years old. Their CIA criterion for
premenopausal patients was no menses during months
7–9 from randomization (Colleoni et al. 2009). Amenor-
rhea induced by modern-day chemotherapies appears to
be characterized by rapid occurrence and is age-non-
specific and transient, contrary to the features of first
generation chemotherapy, such as CMF-induced amen-
orrhea, which occurs at an increasing rate with the pas-
sage of time, shows resistance in younger-aged patients,
and is permanent.
Docetaxel, given after anthracycline-containing regimens,
induced muscle and joint pain in 53–87% of patients(Saibil et al. 2010; Eckhoff et al. 2011). Taxanes (pacli-
taxel and docetaxel) can induce arthralgia and myalgia
in up to 75% of patients (Nugalieva et al. 2010). There
are several differences in the toxicity profiles of doce-
taxel and paclitaxel. Paclitaxel can induce disabling but
transient arthralgia and myalgia, called acute pain syn-
drome, which has been hypothesized to be caused by
neurologic injury (Wolf et al. 2008). The incidence of
docetaxel-induced peripheral neuropathy is much lower
than that of paclitaxel-induced peripheral neuropathy
and is usually mild, disappearing spontaneously after
discontinuation of therapy (Quasthoff & Hartung 2009;
Balayssac et al. 2011).
Symptoms caused by a rapid decline in estrogen levels
induced by docetaxel treatment might be overlooked be-
cause of the diversity of symptoms and the complexity as-
sociated with neuromuscular assessment. There are a few
reports that have explored the relationship between pain
and rapid decline in estrogens such as that caused by sur-
gical menopause (Fang et al. 2009), but low estrogen levels
can lead to an increase in aches and pains. Many women
first report joint pain when they are perimenopausal or
approaching menopause, though whether aches and joint
pains are associated with hormonal changes due to me-
nopausal transition is controversial. The data presented
in this study provide a novel aspect of transient CIA by
measuring serum estradiol and FSH levels during and after
completion of docetaxel-containing chemotherapy, which
can be used to track the impact of adherence to treatment,
especially for younger patients whose biological changes
are more variable than those in patients who are ap-
proaching menopause.
Despite the limitations of our study, which was a small
single-center pilot study, our findings demonstrated that
docetaxel induced a brief period of amenorrhea close to
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positive breast cancer patients. To understand the hor-
monal environment and its relationship with a patient’s
state as well as symptoms caused by docetaxel-containing
chemotherapy, more time points to monitor ovarian
function and more patients are needed. Further study is
warranted.
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